Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
12/2001
12/18/2001US6331631 Reacting 4-piperidinocarboxamide and 1-bromobutane, reduction with lithium aluminum hydride using toluene as solvent
12/18/2001US6331630 Dimeric arylisoquinoline alkaloids and derivatives thereof
12/18/2001US6331623 Pyrrolothiazine and pyrrolothiazepine compounds having serotonin-2 receptor antagonistic and alpha-1-blocking action
12/18/2001US6331622 Processes for preparation of 9, 11-epoxy steroids and intermediates useful therein
12/18/2001US6331613 Nucleotide sequences coding protein associated with cytokine activity; for use in treating allergies, autoimmune diseases and acquired immune deficiency syndrome; for preventing cell differentiation; for activating tissue regeneration
12/18/2001US6331571 Methods of treating and preventing attention deficit disorders
12/18/2001US6331570 Active enantiomer of RARγ-specific agonist
12/18/2001US6331568 Pharmaceutical preparation comprising eicosapentaenoic acid and/or stearidonic acid
12/18/2001US6331566 Heteroatom-interrupted analogs of 15-hydroxyeicosatetraenoic acid and methods of use
12/18/2001US6331565 Inhibit virus dna replication and antigen expression
12/18/2001US6331564 Use of triaryl methane compounds for inhibiting unwanted cellular proliferation associated with inflammatory disease
12/18/2001US6331563 N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl, Sulfanyl, Sulfinyl or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase inhibitors
12/18/2001US6331561 Use of substituted amino-methyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
12/18/2001US6331560 Tumor necrosis factor alpha (TNF-α) inhibiting pharmaceuticals
12/18/2001US6331559 Lipoic acid derivatives and their use in treatment of disease
12/18/2001US6331557 Use of divalent cations for inhibiting erythrocyte dehydration in vivo
12/18/2001US6331556 Benzofuran-4-carboxylic acid amide derivatives used as phosphodiesterase iv or tumor necrosis factor inhibitors
12/18/2001US6331555 Evaluating susceptibility of cancer to compounds which inhibit platelet derived growth factor receptor activity
12/18/2001US6331554 Antipicornaviral compounds, compositions containing them, and methods for their use
12/18/2001US6331553 Inhibitors of nitric oxide synthase; treating cerebrovascular diseases
12/18/2001US6331552 Therapy and prophylaxis of inflammatory disorders, for example of rheumatoid arthritis, or of allergic disorders
12/18/2001US6331551 Cosmetic formulation for treating skin disorder caused by microbial infection, comprising sclareol-like or sclareolide-like compound in cosmetically acceptable carrier
12/18/2001US6331550 Methods of use of quinolone compounds against anaerobic pathogenic bacteria
12/18/2001US6331549 Treatment of urinary stress incontinence, venous insufficiency, venous ulcers, migraine or gastrointestinal disorders
12/18/2001US6331546 Use of 2-amino-3,4-dihydroquinazolines for the production of a medicament for the treatment or prophylaxis of illnesses caused by ischemic conditions
12/18/2001US6331544 Treating positive and negative symptoms of schizophrenia and other psychoses
12/18/2001US6331543 Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
12/18/2001US6331542 Protease inhibitors
12/18/2001US6331540 Enhancing stability of aqueous pharmaceutical composition containing xanthan gum and fluoroquinolone antibiotic drug by adding water-soluble calcium salt
12/18/2001US6331539 Sulfonamide and sulfamide substituted imidazoquinolines
12/18/2001US6331537 Treating neurological disorders in animals
12/18/2001US6331536 Administering to patient in need thereof effective amount of serotonin receptor antagonist to prevent or ameliorate sleep-related breathing disorder
12/18/2001US6331535 Retinyl carbonate derivatives, preparation process and uses
12/18/2001US6331534 Steroids as neurochemical stimulators of the VNO to alleviate pain
12/18/2001US6331533 Administering to cat therapeutically effective amount of bisphosphonate or pharmaceutically acceptable salt thereof to treat feline dental resorptive lesions
12/18/2001US6331532 Mitochondrially targeted antioxidants
12/18/2001US6331529 Treatment of dry eye disease, vaginal dryness, rhinosinusitis and dry mouth
12/18/2001US6331528 Expressing thymidine kinase gene in cell and administering9-(1*,2*-bis(hydroxymethyl)cyclopropan-1*-yl)meth ylguanine
12/18/2001US6331527 Promoter smooth muscle cell expression
12/18/2001US6331526 Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
12/18/2001US6331525 Targeted delivery of genes encoding interferon
12/18/2001US6331522 Antibacterial and antifungal peptide
12/18/2001US6331425 Nucleotide sequences coding enzymatic polypeptide; for use in the diagnosis and treatment of cancer, meningitis and urogenital disorders; for sequencing preferential oligosaccharides
12/18/2001US6331417 Determine amount of target nucleotide sequences in sample; mix sample with control sequences, incubate with nucleotide sequences, perform nucleotide sequence amplification, calculate amount of control and target sequences
12/18/2001US6331411 TopA
12/18/2001US6331410 Polynucleotides encoding a novel pyrR homolog
12/18/2001US6331398 Nucleic acid ligands
12/18/2001US6331317 Pumping active agent and polymer through static mixer forming an emulsion, flowing through a manifold into quench liquid forming microparticles
12/18/2001US6331316 2',3'-dideoxyinosine and methacrylic acid copolymer core; resistance to disintegration; drug release properties
12/18/2001US6331315 Powder compositions of unilamellar liposomes
12/18/2001US6331314 Amphiphilic substances is pumped to a high-pressure homogenizer with nozzle of hard ceramic plate, liposome dispersion
12/18/2001US6331313 Controlled-release biocompatible ocular drug delivery implant devices and methods
12/18/2001US6331298 Wound healing and treatment of fibrotic disorders
12/18/2001US6331296 Food additives which affect conformationally altered proteins
12/18/2001US6331293 Dimer amidopropyl dimethyl phospholipids as barrier compounds
12/18/2001US6331286 Methods for high energy phototherapeutics
12/18/2001CA2235967C Diarylethylene metallocene derivatives, their processes of preparation and pharmaceutical compositions containing said derivatives
12/18/2001CA2221448C Antisense oligonucleotide modulation of raf gene expression
12/18/2001CA2220182C Method of altering the contents of eggs
12/18/2001CA2213815C Pyrrolidinyl hydroxamic acid compounds and their production process
12/18/2001CA2204290C Benzimidazole derivatives, their production and use
12/18/2001CA2202484C Use of indole derivatives for the treatment of various diseases
12/18/2001CA2192665C Methods of lightening hyperpigmented regions in mammalian skin
12/18/2001CA2178161C Indole derivatives
12/18/2001CA2166470C Pharmacologically active enantiomers
12/18/2001CA2160725C Process for the preparation of a tetrazole derivative in two crystalline forms and novel crystalline form of said derivative
12/18/2001CA2085589C Benzoquinazoline compounds
12/18/2001CA2083143C Process for the preparation of 7.alpha.-alkoxycephem derivatives
12/18/2001CA2082923C Sulfonyl compounds
12/18/2001CA2074215C Improved oral dosing formulations of dideoxy purine nucleosides
12/18/2001CA2063610C Method for the treatment of aging or photo-damaged skin
12/18/2001CA2057917C New class of compounds having a variable spectrum of activities for capsaicin-like responses, compositions and uses thereof
12/18/2001CA2031897C Carbamoyl derivatives
12/15/2001CA2311708A1 Method of treating depression using l-threo-methylphenidate
12/13/2001WO2001094613A2 Methods and compounds for influencing beta3 integrin-dependent intracellular processes
12/13/2001WO2001094612A2 Method for identifying medically valuable active substances
12/13/2001WO2001094550A2 Identification and use of molecular markers indicating cellular reprogramming
12/13/2001WO2001094410A1 Insulin regulated substance (irs-2) induced by pioglitazone, assay and use thereof
12/13/2001WO2001094369A2 Heterocycle derivatives and methods of use for treating anthrax infection
12/13/2001WO2001094368A1 2-aminocarbonyl-9h-purine derivatives
12/13/2001WO2001094367A1 Malto-oligosaccharide derivatives and use thereof
12/13/2001WO2001094358A1 Organophosphorous hydroxamic acid derivatives used as herbicides
12/13/2001WO2001094357A1 Antitumoral compounds
12/13/2001WO2001094353A1 Thiophene derivatives useful as anticancer agents
12/13/2001WO2001094351A1 Caspase inhibitors and uses thereof
12/13/2001WO2001094350A1 6-phenylpyrrolopyrimidinedione derivatives
12/13/2001WO2001094347A1 Tetracyclic diketopiperazine compounds as pdev inhibitors
12/13/2001WO2001094346A1 1,3,8-TRIAZA-SPIRO'4,5!DECAN-4-ONE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS
12/13/2001WO2001094345A2 Derivatives of 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione
12/13/2001WO2001094344A1 Thiazolidinedione salt for treatment of diabetes mellitus
12/13/2001WO2001094343A1 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical
12/13/2001WO2001094342A1 Novel oxazolidinone derivatives and a process for the preparation thereof
12/13/2001WO2001094341A1 Quinazoline derivatives for the treatment of tumours
12/13/2001WO2001094338A1 Admantane derivatives
12/13/2001WO2001094335A2 Methods for producing chiral chromones, chromanes, amino substituted chromanes and intermediates therefor
12/13/2001WO2001094333A2 Process for the preparation of benzoyl substituted bicyclic compounds and chiral benzopyran derivatives
12/13/2001WO2001094325A1 2-aminothiazoline derivatives and their use as no-synthase inhibitors
12/13/2001WO2001094321A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists
12/13/2001WO2001094319A1 Compounds effective as beta-2-adrenoreceptor agonists as well as pde4-inhibitors
12/13/2001WO2001094312A2 Indolinone derivatives as protein kinase/phosphatase inhibitors